Neurodevelopmental Disorder with Microcephaly, Movement Abnormalities, and Seizures

Key Findings

Finding 1 — Disease identity: NEDMIMS is caused by biallelic CHKA variants

NEDMIMS (OMIM #620023) was established by Klöckner et al. (2022, Brain), who identified six individuals from five unrelated families carrying bi-allelic variants in CHKA (gene MIM 118491; 11q13.2). Inheritance is autosomal recessive. The authors state: "We identified six individuals from five families with bi-allelic variants in CHKA presenting with severe global developmental delay, epilepsy, movement disorders and microcephaly" (PMID: 35202461). The four cardinal features give the disorder its name. Yeast complementation and structural modeling showed the variants "reduce the enzymatic activity of CHKA and confer a significant impairment of the first enzymatic step of the Kennedy pathway," establishing a loss-of-function mechanism.

Finding 2 — CHKA loss cripples the CDP-choline (Kennedy) pathway

Choline kinase (isoforms CHKα/CHKβ) catalyzes ATP + choline → ADP + phosphocholine, the first committed step of de novo PC synthesis; phosphocholine is converted to CDP-choline (PCYT1A/B) and then to phosphatidylcholine. Klöckner et al. note: "The Kennedy pathways catalyse the de novo synthesis of phosphatidylcholine and phosphatidylethanolamine, the most abundant components of eukaryotic cell membranes" (PMID: 35202461). This is corroborated by Chen et al.: "Choline kinases possess enzyme activity that catalyses the conversion of choline to phosphocholine, which is further converted to cytidine diphosphate-coline (CDP-choline) in the biosynthesis of phosphatidylcholine (PC)" (PMID: 27769579). Four of ten Kennedy-pathway genes were already disease-associated before NEDMIMS: CHKB (megaconial muscular dystrophy), PCYT1A (cone-rod dystrophy/bone), PCYT2 and SELENOI (spastic paraplegia).

Finding 3 — CHKA is not haploinsufficient, consistent with recessive disease

gnomAD constraint for CHKA (ENSG00000110721): pLI ≈ 4.3×10⁻⁶, observed/expected LoF = 0.57 (90% CI 0.43–0.75; LOEUF 0.75), LoF Z = 2.86, missense Z ≈ 0. Heterozygous loss-of-function is tolerated in the general population (carriers unaffected); disease requires biallelic variants — fully consistent with autosomal recessive inheritance and the disorder's ultra-rarity/consanguinity association.

Finding 4 — Complete Chka loss is embryonic lethal; disease alleles are hypomorphic

Wu et al.: "Disruption of murine Chka leads to embryonic lethality, whereas a spontaneous genomic deletion in murine Chkb results in neonatal forelimb bone deformity and hindlimb muscular dystrophy" (PMID: 20026284). Because a null Chka genotype is incompatible with life in mice, viable human disease alleles must retain residual activity (hypomorphic). The paralogous disorder offers a therapeutic proof-of-concept: "Intramuscular gene therapy post-disease onset using an adeno-associated viral 6 (AAV6) vector carrying a functional copy of Chkb is also capable of rescuing the dystrophy phenotype" (PMID: 31216357). Human variants were additionally validated by yeast (S. cerevisiae) complementation.

Finding 5 — Full phenotype spectrum with HPO frequencies (n=6, Klöckner 2022)

Fully penetrant core features (6/6, 100%): microcephaly (HP:0000252), severe global developmental delay (HP:0011344), delayed gross motor development (HP:0002194), absent speech (HP:0001344), epileptic encephalopathy (HP:0200134), hypertonia (HP:0001276). Highly frequent: hyperreflexia (HP:0001347, 5/5), inability to walk (HP:0002540, 5/6). Common: infantile onset (HP:0003593, 4/6), short stature (HP:0004322, 4/6), nystagmus (HP:0000639, 3/6), aggressive behavior (HP:0000718, 3/6), scoliosis (HP:0002650, 3/6). Movement axis: dyskinesia (HP:0100660, 2/6), choreoathetosis (HP:0001266, 1/6), rigidity (HP:0002063, 1/6). Less frequent (1/6): self-injury (HP:0100716), sleep disturbance (HP:0002360), autistic behavior (HP:0000729), hyperactivity (HP:0000752), cerebral visual impairment (HP:0100704), feeding difficulties (HP:0011968), high palate (HP:0000218), kidney stone (HP:0000787). Neuroimaging: CNS hypomyelination (HP:0003429, 2/5), thin corpus callosum (HP:0033725, 1/5). Source: "…severe global developmental delay, epilepsy, movement disorders and microcephaly" (PMID: 35202461).

Finding 6 — CHKA pathogenic variant spectrum (ClinVar; NM_001277.3)

Pathogenic/Likely-pathogenic NEDMIMS variants span classes: c.1030G>T p.(Gly344Ter) (nonsense); c.14dup p.(Cys6fs) (frameshift); c.1021T>C p.(Phe341Leu), c.580C>T p.(Pro194Ser), c.421C>T p.(Arg141Trp) (missense). Full CHKA ClinVar record (94 entries): 7 Pathogenic, 10 Likely pathogenic, 54 VUS, 5 Likely benign — though many "Pathogenic" entries are large 11q contiguous-gene CNVs, not NEDMIMS-specific. Variants are germline, biallelic; consequence is loss-of-function / reduced choline kinase activity (hypomorphic).

Finding 7 — CHKA protein: cytosolic choline/ethanolamine kinase

CHKA (UniProt P35790; HGNC:1937; NCBIGene:1119; ENSG00000110721; 11q13.2). Reactions: choline + ATP → phosphocholine + ADP (GO:0004103) and ethanolamine + ATP → phosphoethanolamine + ADP (GO:0004305). Processes: PC biosynthesis (GO:0006656), CDP-choline pathway (GO:0006657), PE biosynthesis (GO:0006646). Localization: cytosol (GO:0005829), cytoplasm (GO:0005737), lipid droplet (GO:0005811). CHEBI entities: choline (CHEBI:15354), ATP (CHEBI:30616), phosphocholine (CHEBI:295975), CDP-choline (CHEBI:16436), phosphatidylcholine (CHEBI:16110), ethanolamine (CHEBI:57603).

Finding 8 — Orthologs and pathway memberships

CHKA (HomoloGene 88575) orthologs: mouse Chka (12660), rat Chka (29194), zebrafish chka (558499), C. elegans (180703), plus dog/cow/chicken/chimp. Pathways: KEGG hsa00564 (glycerophospholipid metabolism), hsa05231 (choline metabolism in cancer); WikiPathways WP3933 (Kennedy pathway); Reactome R-HSA-1483191 (synthesis of PC). No naturally occurring CHKA-equivalent disease is catalogued in OMIA for domestic animals.

Finding 9 — Rich experimental structural data for variant mapping

Human CHKα (457 aa) has ≥5 high-resolution PDB structures (2IG7, 2CKQ, 2CKO, 3F2R, 2CKP). Architecture: disordered N-terminal region (~res 1–86) + choline/ethanolamine kinase catalytic domain (~res 80–457); ATP/substrate-contacting residues include 117–123, 119–121, 146, 207–213, 308, 330. NEDMIMS missense variants (p.Arg141Trp, p.Pro194Ser, p.Phe341Leu) fall within/adjacent to the catalytic domain, structurally consistent with the measured reduction in activity (PMID: 35202461).

Mechanistic Model / Interpretation

Causal chain

Biallelic hypomorphic CHKA variants (missense / nonsense / frameshift)
│  (null is embryonic-lethal → alleles retain residual activity)
▼
Reduced choline kinase activity
│  ATP + choline ──X──▶ phosphocholine   (first committed step)
▼
Impaired CDP-choline (Kennedy) pathway flux
▼
Deficient de novo phosphatidylcholine (± phosphatidylethanolamine) synthesis
│  PC = most abundant membrane phospholipid
▼
Inadequate membrane phospholipid supply in the developing CNS
│  (neuronal membrane biogenesis, myelination, synaptogenesis)
▼
┌─────────────────────────────────────────────────────────────┐
│ Microcephaly  │ Hypomyelination/thin CC │ Epileptic          │
│ (HP:0000252)  │ (HP:0003429/HP:0033725) │ encephalopathy     │
│               │                         │ (HP:0200134)       │
│ Severe global DD / absent speech (HP:0011344 / HP:0001344)   │
│ Mixed movement disorder: hypertonia + dyskinesia/chorea      │
│ (HP:0001276 / HP:0100660 / HP:0001266)                       │
└─────────────────────────────────────────────────────────────┘

Upstream vs downstream. The upstream trigger is the genetic lesion reducing CHKA catalytic output; the immediate downstream node is diminished phosphocholine production and reduced Kennedy-pathway flux to PC. Distal clinical consequences (microcephaly, hypomyelination, seizures, movement disorder) reflect the developing brain's exceptional dependence on continuous membrane phospholipid biosynthesis for neuronal proliferation, axonal/dendritic membrane expansion, and myelin production. CHKA's bifunctional ethanolamine kinase activity (GO:0004305) means PE synthesis may also be partly compromised, compounding the deficit.

Placement within the Kennedy-pathway disorder family

The tissue-specific expression of the two paralogs (Wu et al., PMID: 20026284) explains why α-isoform loss manifests as a neurodevelopmental (rather than myopathic) disease. Cell types: neurons (CL:0000540), oligodendrocytes (CL:0000128; hypomyelination), and neural progenitors (microcephaly). Subcellular convergence: cytosolic phosphorylation (GO:0005829) → ER-based PC assembly → deficient plasma-membrane / myelin phospholipid.

Section-by-Section Disease Characterization

1. Disease Information

• Overview: ultra-rare autosomal recessive Mendelian neurodevelopmental disorder defined by microcephaly, severe global developmental delay, epileptic encephalopathy, and a mixed movement disorder, caused by biallelic CHKA variants that impair phosphatidylcholine biosynthesis.
• Identifiers: OMIM #620023; gene OMIM 118491; MONDO :0859282; UMLS C5774208; MedGen linked; HGNC:1937; NCBIGene:1119; Ensembl ENSG00000110721; UniProt P35790. No dedicated Orphanet, ICD-10/ICD-11, or MeSH code was identified (maps to broad categories: ICD-10 Q02 microcephaly / G40 epilepsy / F79 intellectual disability).
• Synonyms: NEDMIMS; CHKA-related neurodevelopmental disorder; CHKA-related developmental and epileptic encephalopathy with microcephaly; choline kinase alpha deficiency (neurodevelopmental form).
• Source type: aggregated disease-level knowledge from an individual-patient case series (n=6), not EHR/registry data.

2. Etiology

• Causal factor: purely genetic — biallelic hypomorphic loss-of-function variants in CHKA; no environmental/infectious cause. Klöckner et al. showed variants "reduce the enzymatic activity of CHKA" (PMID: 35202461).
• Genetic risk factors: inheriting two damaging CHKA alleles; consanguinity/founder homozygosity is the dominant risk context. CHKA is not haploinsufficient (pLI≈0), so carriers are unaffected. No proven modifier genes (paralog CHKB and downstream PCYT1A/PCYT2/SELENOI/CHPT1/CEPT1 are plausible but unproven modifiers).
• Environmental/protective factors: none established. Dietary choline is a theoretical (untested) substrate-supply modifier.
• Gene–environment interactions: none documented.

3. Phenotypes

See Finding 5 for the HPO-annotated frequency profile. Phenotype types span clinical signs (microcephaly, hypertonia, hyperreflexia), developmental deficits (global DD, absent speech, inability to walk), behavioral changes (aggression, self-injury, autistic behavior, hyperactivity, sleep disturbance), and neuroimaging abnormalities (hypomyelination, thin corpus callosum). Onset: infantile (4/6) to childhood (2/6). Severity: severe-to-profound. Progression: developmental delay static-to-slowly-progressive; microcephaly progressive/postnatal; epilepsy often refractory. Laboratory: no diagnostic biochemical marker. QoL impact: profound — non-verbal, non-ambulatory in most, lifelong dependent care; no disease-specific QoL instrument data.

4. Genetic / Molecular Information

• Causal gene: CHKA (HGNC:1937; MIM 118491; 11q13.2; NM_001277.3 / NP_001268.1). See Finding 6 for variants.
• Classification landscape: 94 ClinVar records (7 P, 10 LP, 54 VUS, 5 LB); ACMG/AMP-based, supported by functional data + rarity + recessive segregation.
• Allele frequency: ultra-rare/absent in gnomAD; heterozygous LoF tolerated.
• Origin: germline, biallelic (CHKA somatic overactivity is a cancer phenomenon, not relevant here).
• Functional consequence: loss-of-function/hypomorphic; not gain-of-function or dominant-negative.
• Modifier/epigenetic/chromosomal: none NEDMIMS-specific; large 11q13 CNVs cause distinct contiguous-gene phenotypes.

5. Environmental Information

Not applicable — no toxic, lifestyle, or infectious contributors. (Diagnostic pitfall: intracranial calcifications in the broader spectrum can mimic congenital TORCH infection.)

6. Mechanism / Pathophysiology

Detailed above. Pathway: CDP-choline / Kennedy pathway (WP3933; KEGG hsa00564; Reactome R-HSA-1483191). Core defect: reduced choline kinase activity (GO:0004103) → impaired PC biosynthesis (GO:0006656). Protein dysfunction: hypomorphic activity reduction with disease missense residues mapping to the catalytic domain (PDB 2IG7, 2CKQ, etc.). CHKA also has a non-catalytic scaffolding role (binds c-Src SH3 via its poly-proline region, PMID: 31745227); relevance to NEDMIMS unproven. No immune, infectious, or storage component. No patient-level omics (transcriptomic/proteomic/lipidomic) published; predicted lipidomic signature = reduced PC species.

7. Anatomical Structures Affected

• Organ/system: brain/CNS (UBERON:0000955, UBERON:0001017) — cortex (UBERON:0000956), white matter (UBERON:0002316), corpus callosum (UBERON:0002336); secondary skeletal (scoliosis; UBERON:0001130), growth, occasional renal.
• Tissue/cell: nervous tissue — neurons (CL:0000540), oligodendrocytes (CL:0000128; hypomyelination); no primary muscle pathology (contrast CHKB).
• Subcellular: cytosol (GO:0005829), lipid droplet (GO:0005811); pathology converges on cellular membranes (ER GO:0005783, plasma/myelin membrane).
• Localization: bilateral, symmetric, diffuse; not focal.

8. Temporal Development

• Onset: congenital-to-infantile (HP:0003593 4/6; childhood HP:0011463 2/6); chronic/insidious-developmental, with epilepsy sometimes acute in presentation.
• Progression: static-to-slowly-progressive developmental deficits; progressive microcephaly; often refractory epileptic encephalopathy; no discrete stages.
• Course/duration: chronic, lifelong, non-remitting; no spontaneous remission of core disability.
• Critical period: prenatal–early-postnatal brain growth/myelination window — the theoretical window for metabolic intervention.

9. Inheritance and Population

• Inheritance: autosomal recessive (HP:0000007); biallelic (homozygous or compound heterozygous).
• Penetrance: complete for the core tetrad in reported biallelic cases (small denominator). Expressivity: variable for secondary features.
• Anticipation/mosaicism: not applicable (not a repeat disorder).
• Founder/consanguinity: consanguinity central; likely private/founder alleles per family rather than one global founder.
• Carrier frequency: not formally estimated; expected very low.
• Epidemiology: ultra-rare; prevalence/incidence not established (<~10 individuals reported; 6 in the defining paper). Demographics: reported families of Middle Eastern/North African/South Asian background (ascertainment via homozygosity); no sex bias expected (autosomal); pediatric diagnosis.

10. Diagnostics

• Genetic testing is definitive: trio WES/WGS or a neurodevelopmental/epilepsy/microcephaly gene panel including CHKA; confirm biallelic status + segregation. GeneMatcher enabled cohort assembly. CMA/karyotype/FISH help exclude 11q CNVs but are typically normal in NEDMIMS. mtDNA/repeat testing not indicated.
• No biochemical biomarker; routine metabolic screens unrevealing.
• Imaging: brain MRI may be normal or show hypomyelination/leukoencephalopathy, thin corpus callosum, ventriculomegaly, cortical abnormalities (± calcifications on CT). EEG: epileptiform/encephalopathic patterns. Serial head-circumference documents progressive microcephaly.
• Differential diagnosis: other Kennedy-pathway disorders (CHKB megaconial dystrophy — muscle-predominant, megaconial mitochondria; PCYT2/SELENOI HSP; PCYT1A retinal/skeletal), PPFIBP1-related disorder (microcephaly + periventricular calcifications), primary microcephaly (MCPH) genes, congenital TORCH infections, other early-infantile DEEs, hypomyelinating leukodystrophies.
• Screening: not part of newborn screening; carrier/cascade and prenatal/PGT-M feasible for known biallelic families.

11. Outcome / Prognosis

• Function: severe-to-profound; most non-ambulatory (inability to walk 5/6) and non-verbal (absent speech 6/6) with refractory epilepsy → lifelong dependence (ICF: severe limitations in mobility, communication, self-care).
• Survival/mortality: not systematically quantified; early-onset refractory epileptic encephalopathy carries elevated risk (including generic SUDEP risk). Long-term life expectancy undetermined.
• Complications: refractory seizures, aspiration/feeding difficulties, failure to thrive/short stature, scoliosis, contractures, behavioral/self-injury and sleep problems, cerebral visual impairment, rare nephrolithiasis.
• Recovery potential: none for core deficit (irreversible developmental involvement).
• Prognostic factors: presumed correlation of residual CHKA activity (allele severity) and seizure control with outcome — plausible, not statistically established. No validated prognostic biomarker.

12. Treatment

No disease-specific or curative therapy. Management is symptomatic, supportive, multidisciplinary. - Pharmacotherapy: anti-seizure medications (NCIT: Anticonvulsant Agent); spasticity/movement agents (baclofen, trihexyphenidyl, focal botulinum toxin); behavioral/sleep management. No CHKA-specific pharmacogenomics. - Advanced/experimental (conceptual only): choline/CDP-choline (citicoline) substrate supplementation — precedent in the paralogous CHKB disorder (Chen et al. propose CDP-choline supplementation may be beneficial, PMID: 27769579) — efficacy in CHKA unproven. Gene replacement — AAV6-Chkb rescued the rmd mouse (PMID: 31216357), a template for future CHKA work (CNS delivery/timing are hurdles). CHKA inhibitor trials exist but are oncology programs (opposite direction — irrelevant to this LoF disorder). - Surgical/interventional: epilepsy surgery generally not applicable (diffuse/genetic); orthopedic scoliosis/contracture management; gastrostomy as needed. - Supportive/rehabilitative (mainstay): physical, occupational, and speech/communication therapy; nutrition; vision/orthopedic care; caregiver support (NCIT: Rehabilitation Therapy).

13. Prevention

• Primary: reproductive genetics only — genetic counseling for consanguineous/at-risk couples, carrier screening, and, for couples with a prior affected child, prenatal diagnosis or PGT-M.
• Secondary: early molecular diagnosis → early seizure control and early developmental/rehabilitation intervention within the critical window.
• Tertiary: complication prevention (seizure management, aspiration precautions/nutrition, scoliosis/contracture prevention, behavioral/sleep support).
• Immunization/public-health/environmental/prophylaxis: not applicable (non-infectious, non-environmental).

14. Other Species / Natural Disease

• Affected species (natural): human (Homo sapiens, NCBI:txid9606) only. No naturally occurring CHKA-equivalent disease in OMIA for companion animals/livestock. (The spontaneous Chkb rmd mouse is the paralog.)
• Orthologs: mouse Chka (12660, txid10090), rat (29194, txid10116), zebrafish (558499, txid7955), C. elegans (180703, txid6239), plus dog/cattle/chicken/chimp (HomoloGene 88575). Deeply conserved (metazoa → yeast CKI1).
• Comparative biology: Kennedy pathway deeply conserved; yeast complementation of human variants demonstrates conserved catalytic function (PMID: 35202461). No zoonotic/veterinary relevance (genetic disorder).

15. Model Organisms

• Mouse (MGI): homozygous Chka KO is embryonic lethal (PMID: 20026284) → CHKA essentiality; a conditional/hypomorphic or humanized knock-in model is needed to recapitulate NEDMIMS. The Chkb rmd mouse models the paralogous disease and is AAV-rescuable (PMID: 31216357).
• Yeast (SGD): cell-based complementation validated reduced activity of patient variants (PMID: 35202461).
• C. elegans (WormBase) and zebrafish (ZFIN): orthologs available; no published NEDMIMS-specific model (zebrafish is a tractable CNS/microcephaly option).
• Cellular/iPSC/organoid: none published; patient iPSC cortical neurons/organoids with lipidomics is the clear next step.
• Recapitulation: no model fully reproduces the human CNS phenotype; existing systems establish loss of enzymatic function/essentiality and enable variant functional testing and therapeutic proof-of-concept.

Evidence Base

Peripheral literature (PPFIBP1-, ACBD6-, RBL2-, BORCS5-, tubulin-, GABRB2-related disorders) was reviewed to establish the differential-diagnostic landscape of monogenic microcephaly–DD–epilepsy–movement-disorder syndromes; these overlap clinically but are mechanistically distinct from CHKA/Kennedy-pathway disease.

Limitations and Knowledge Gaps

1. Extremely small evidence base. The clinical definition rests on one case series (n=6, 5 families). Prevalence, penetrance detail, natural history, survival, and genotype–phenotype correlations are essentially uncharacterized; phenotype frequencies (Finding 5) will shift as cases accrue.
2. No patient-level molecular profiling. No transcriptomic/proteomic/lipidomic/metabolomic patient datasets; no validated biomarker. Direct demonstration of reduced brain PC in patients is lacking (mechanism inferred from enzymology + models).
3. No dedicated in-vivo NEDMIMS model. Complete Chka KO is embryonic lethal, so a hypomorphic/conditional CNS model recapitulating the human disease is not yet available; yeast validates activity loss but cannot model neurodevelopment.
4. Ontology/identifier gaps. No Orphanet, ICD-10/ICD-11, or MeSH-specific code located; classification relies on OMIM/MONDO/UMLS.
5. Therapeutics unproven. Choline/CDP-choline supplementation and gene replacement are only theoretically motivated (by paralog biology); no experimental or clinical data in NEDMIMS.

Proposed Follow-up Experiments / Actions

1. International case ascertainment (GeneMatcher / Matchmaker Exchange): expand the cohort to refine phenotype frequencies, penetrance, expressivity, natural history, and genotype–phenotype correlations.
2. Patient lipidomics/metabolomics: measure phosphocholine, CDP-choline, and PC species in patient fibroblasts, plasma, and neural cells to establish a candidate biomarker and confirm the membrane-lipid deficit in vivo.
3. Faithful neuronal disease model: generate patient-derived iPSC cortical neurons/organoids or a conditional/hypomorphic Chka mouse (bypassing embryonic lethality) to test whether reduced activity causes microcephaly, hypomyelination, and hyperexcitability, and to define the developmental critical window.
4. Structure–function mapping: dock disease missense variants (p.Arg141Trp, p.Pro194Ser, p.Phe341Leu) onto CHKα structures (PDB 2IG7/2CKQ) and correlate predicted destabilization/active-site perturbation with residual activity, to build a variant-effect framework for reclassifying the 54 current VUS.
5. Therapeutic proof-of-concept: test choline/CDP-choline (citicoline) supplementation and AAV-CHKA gene delivery in patient iPSC neurons and any hypomorphic mouse model, leveraging the AAV6-Chkb rmd-mouse rescue precedent (PMID: 31216357).
6. Registry and counseling infrastructure: establish a NEDMIMS/CHKA registry, standardized genetic-counseling/prenatal-testing pathways for affected (often consanguineous) families, and pursue Orphanet/ICD-11 cataloguing with carrier-frequency estimation.

Report compiled from 9 confirmed findings and 32 reviewed papers across 5 investigation iterations. Evidence source types: predominantly human clinical (defining case series), supported by model organism (mouse, yeast, C. elegans), in vitro (enzyme/structural), and computational (gnomAD constraint, structural modeling) data.

Artifacts

• OpenScientist final report
• OpenScientist final report

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.